The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 21, 2021
Filed:
Aug. 02, 2017
Applicants:
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);
University of South Florida, Tampa, FL (US);
Inventors:
Assignees:
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);
University of South Florida, Tampa, FL (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 7/08 (2006.01); C12N 15/117 (2010.01); A61K 47/54 (2017.01); C07K 14/705 (2006.01); A61P 35/00 (2006.01); A61K 38/10 (2006.01);
U.S. Cl.
CPC ...
A61K 47/549 (2017.08); A61K 38/00 (2013.01); A61K 38/10 (2013.01); A61P 35/00 (2018.01); C07K 7/08 (2013.01); C07K 14/70596 (2013.01); C07K 2319/33 (2013.01); C12N 15/117 (2013.01); C12N 2310/17 (2013.01); C12N 2310/3513 (2013.01); C12N 2320/32 (2013.01);
Abstract
Disclosed are compositions and methods for targeted treatment of cancers, such as TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target lytic peptides to TLR9-expressing malignant cells are disclosed.